Found January 23, 2013 on The Flying Knee MMA:
It has been a long time coming for Alistair Overeem. The dutch heavyweight has been out of action for over a year dating back to his octagon debut at UFC 141 where he retired former champ Brock Lesnar in devastating fashion. Soon afterwards he was found to have a testosterone to epitestosterone ratio of 14:1 (the legal limit in Nevada is 6:1) after which the Nevada State Athletic Commission refused to renew his licensure for nine months. After serving his nine month retroactive suspension, Overeem, having succumbed to over eight drug tests, re-applied for licensure and was granted it.  Before he can regain his former no.1 contender status, Overeem will first meet Brazilian heavyweight Antonio ‘Bigfoot’ Silva, who is coming off a knockout win over Jackson’s MMA prospect Travis Browne. Whilst the former Strikeforce heavyweight champion is aware of the obstacle in front of him, he does not believe that it is one that he will be unable to clear come February 2nd. “I am very pleased to b...

Alistair Overeem Hits The Cover Of UFC 360

Alistair is all over the place right now- documentaries, UFC promos, and a fight that could propel him into a shot at the UFC heavyweight title.  Can’t wait to see the Demolition Man back in the Octagon. The Reem 3.0 Overeem’s World

“The Reem Returns” is Live at

On Saturday, February 2, UFC Heavyweight Alistair Overeem will return to the Octagon to take on Antonio “Bigfoot” Silva at UFC 156, one of the most pivotal heavyweight fights in the storied career of the Dutch kickboxing champion turned pro mixed martial artist. However, the journey that brings him to this very crossroad began years [...]
Today's Best Stuff
For Bloggers

Join the Yardbarker Network for more promotion, traffic, and money.

Company Info
What is Yardbarker?

Yardbarker is the largest network of sports blogs and pro athlete blogs on the web. This site is the hub of the Yardbarker Network, where our editors and algorithms curate the best sports content from our network and beyond.